Alterity Therapeutics Limited (ATHE) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ATHE Revenue Growth
ATHE Revenue Analysis (2014–2025)
As of May 8, 2026, Alterity Therapeutics Limited (ATHE) generated trailing twelve-month (TTM) revenue of $9.5 million, reflecting explosive growth of +80.9% year-over-year. The most recent quarter (Q4 2025) recorded $3.8 million in revenue, up 138.7% sequentially.
Looking at the longer-term picture, ATHE's historical revenue data shows a 3-year CAGR of +2.0%. The company achieved its highest annual revenue of $5.4 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including PRTA (-58.0% YoY), ACAD (+9.9% YoY), and IONS (+47.5% YoY), ATHE has outperformed the peer group in terms of revenue growth. Compare ATHE vs PRTA →
ATHE Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ATHECurrent | $9M | +80.9% | - | -268.0% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% |
ATHE Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $5.4M | +35.3% | $5.3M | 97.7% | $-14,574,286 | -268.0% |
| 2024 | $4.0M | +2.6% | $3.8M | 94.7% | $-19,601,709 | -487.7% |
| 2023 | $3.9M | -23.6% | $3.6M | 92.7% | $-14,636,142 | -373.7% |
| 2022 | $5.1M | +18.1% | $4.8M | 92.9% | $-15,501,987 | -302.6% |
| 2021 | $4.3M | - | $4.0M | 91.7% | $-15,178,544 | -349.8% |
| 2020 | $0 | -100.0% | $-112,427 | - | $-10,414,021 | - |
| 2019 | $109K | -46.0% | $79K | 72.6% | $-12,713,861 | -11713.7% |
| 2018 | $201K | +51.9% | $179K | 89.2% | $-7,770,297 | -3862.5% |
| 2017 | $132K | -7.2% | $111K | 83.9% | $-6,881,863 | -5197.9% |
| 2016 | $143K | -19.3% | $120K | 84.0% | $-8,586,798 | -6019.2% |
See ATHE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ATHE Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ATHE vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonATHE — Frequently Asked Questions
Quick answers to the most common questions about buying ATHE stock.
Is ATHE's revenue growth accelerating or slowing?
ATHE revenue is accelerating at +80.9% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $9M. Growth momentum has increased versus prior periods.
What is ATHE's long-term revenue growth rate?
Alterity Therapeutics Limited's 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +80.9% is above this long-term average.
How is ATHE's revenue distributed by segment?
ATHE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.